Skip to main content

Advertisement

SpringerLink
Log in

Resveratrol in the Prevention and Treatment of Coronary Artery Disease

  • Nutrition (William S. Harris, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

An Erratum to this article was published on 21 October 2011

Abstract

Resveratrol is a polyphenolic compound found in red wine that is believed to be responsible for its beneficial cardiovascular effects. Extensive research in the past several decades has identified multiple mechanisms by which resveratrol modifies the cardiovascular risk factors that lead to coronary artery disease, yet translation to the clinical arena has been unexpectedly slow. In this article, we review the existing evidence regarding the beneficial effects of resveratrol and briefly discuss its potential therapeutic applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18–209. This article details the most recent national statistics for coronary artery disease and other cardiovascular diseases.

    Article  PubMed  Google Scholar 

  2. Minino AM, Xu J, Kochanek KD, et al. Death in the United States, 2007. NCHS Data Brief. 2009;26:1–8.

    PubMed  Google Scholar 

  3. Petrovski G, Gurusamy N, Das DK. Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci. 2011;125:22–33.

    Article  Google Scholar 

  4. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339(8808):1523–6. This is the seminal work describing the statistics behind the French paradox.

    Article  PubMed  CAS  Google Scholar 

  5. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329(25):1829–34.

    Article  PubMed  CAS  Google Scholar 

  6. Jackson R, Scragg R, Beaglehole R. Alcohol consumption and risk of coronary heart disease. BMJ. 1991;303(6796):211–6.

    Article  PubMed  CAS  Google Scholar 

  7. Gronbaek M, Becker U, Johansen D, et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med. 2000;133(6):411–9.

    PubMed  CAS  Google Scholar 

  8. Wannamethee SG, Shaper AG. Type of alcoholic drink and risk of major coronary heart disease events and all-cause mortality. Am J Public Health. 1999;89(5):685–90.

    Article  PubMed  CAS  Google Scholar 

  9. Lazarus NB, Kaplan GA, Cohen RD, et al. Change in alcohol consumption and risk of death from all causes and from ischaemic heart disease. BMJ. 1991;303(6802):553–6.

    Article  PubMed  CAS  Google Scholar 

  10. Colditz GA, Branch LG, Lipnick RJ, et al. Moderate alcohol and decreased cardiovascular mortality in an elderly cohort. Am Heart J. 1985;109(4):886–9.

    Article  PubMed  CAS  Google Scholar 

  11. Friedman LA, Kimball AW. Coronary heart disease mortality and alcohol consumption in Framingham. Am J Epidemiol. 1986;124(3):481–9.

    PubMed  CAS  Google Scholar 

  12. Saremi A, Arora R. The cardiovascular implications of alcohol and red wine. Am J Ther. 2008;15(3):265–77.

    Article  PubMed  Google Scholar 

  13. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91(9):2488–96.

    PubMed  CAS  Google Scholar 

  14. •• Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun. 2008;374(1):55–9. This work elegantly summarized the effects of resveratrol on serum cholesterol and its components, and relates those effects to pathologic findings.

    Article  PubMed  CAS  Google Scholar 

  15. Rocha KK, Souza GA, Ebaid GX, et al. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol. 2009;47(6):1362–7.

    Article  PubMed  CAS  Google Scholar 

  16. •• Robich M, Osipov R, Nezafat R, et al. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010;122(11 Suppl):S142–9. This is the only work to date investigating the effects of resveratrol supplementation on angiogenesis and myocardial perfusion in the setting of ongoing myocardial ischemia.

    Article  PubMed  CAS  Google Scholar 

  17. • Cho IJ, Ahn JY, Kim S, et al. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun. 2008;367(1):190–4. This article suggests a possible mechanism for many of the beneficial effects of resveratrol.

    Article  PubMed  CAS  Google Scholar 

  18. Wang Z, Zou J, Cao K, et al. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med. 2005;16(4):533–40.

    PubMed  CAS  Google Scholar 

  19. Wilson T, Knight TJ, Beitz DC, et al. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci. 1996;59(1):PL 15–21.

    Article  CAS  Google Scholar 

  20. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–41.

    Article  PubMed  CAS  Google Scholar 

  21. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275(23):17527–35.

    Article  PubMed  CAS  Google Scholar 

  22. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 2002;161(2):245–54.

    Article  PubMed  CAS  Google Scholar 

  23. Berrougui H, Grenier G, Loued S, et al. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009;207(2):420–7.

    Article  PubMed  CAS  Google Scholar 

  24. Li Y, Cao Z, Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res. 2006;53(1):6–15.

    Article  PubMed  CAS  Google Scholar 

  25. • Deng YH, Alex D, Huang HQ, et al. Inhibition of TNF-α-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4′-trimethoxystilbene. Phytother Res. 2011;25(3):451–7. This is an elegant study showing the effects of resveratrol on monocyte recruitment and activation.

    PubMed  CAS  Google Scholar 

  26. Zhong M, Cheng GF, Wang WJ, et al. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine. 1999;6(2):79–84.

    Article  PubMed  CAS  Google Scholar 

  27. Chung EY, Kim BH, Hong JT, et al. Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem. 2010(Epub ahead of print).

  28. Park DW, Baek K, Kim JR, et al. Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med. 2009;41(3):171–9.

    Article  PubMed  CAS  Google Scholar 

  29. Venkatesan B, Valente AJ, Reddy VS, et al. Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am J Physiol Heart Circ Physiol. 2009;297(2):H874–86.

    Article  PubMed  CAS  Google Scholar 

  30. Ekshyyan VP, Hebert VY, Khandelwal A, et al. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol. 2007;50(1):83–93.

    Article  PubMed  CAS  Google Scholar 

  31. Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun. 2000;274(1):61–7.

    Article  PubMed  CAS  Google Scholar 

  32. Li L, Gao P, Zhang H, et al. SIRT1 inhibits angiotensin II-induced vascular smooth muscle cell hypertrophy. Acta Biochim Biophys Sin (Shanghai). 2011;43(2):103–9.

    Article  CAS  Google Scholar 

  33. Schroecksnadel K, Winkler C, Wirleitner B, et al. Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro. Clin Chem Lab Med. 2005;43(10):1084–8.

    Article  PubMed  CAS  Google Scholar 

  34. Olas B, Wachowicz B, Saluk-Juszczak J, et al. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb Res. 2002;107(3–4):141–5.

    Article  PubMed  CAS  Google Scholar 

  35. Yang Y, Wang X, Zhang L, et al. Inhibitory effects of resveratrol on platelet activation inducded by thromboxane a(2) receptor agonist in human platelets. Am J Chin Med. 2011;39(1):145–59.

    Article  PubMed  CAS  Google Scholar 

  36. • Lin KH, Hsiao G, Shih CM, et al. Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc Res. 2009;83(3):575–85. This article reports an unexpected and interesting effect of resveratrol on platelets.

    Article  PubMed  CAS  Google Scholar 

  37. Boodhwani M, Sodha NR, Mieno S, et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation. 2007;116(11 Suppl):I31–7.

    PubMed  Google Scholar 

  38. Gnoni GV, Paglialonga G. Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur J Clin Invest. 2009;39(3):211–8.

    Article  PubMed  CAS  Google Scholar 

  39. •• Kim S, Jin Y, Choi Y, et al. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011;81(11):1343–51. This study details several possible molecular mechanisms for the anti-obesity effects of resveratrol.

    Article  PubMed  CAS  Google Scholar 

  40. Dal-Pan A, Blanc S, Aujard F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol. 2010;10:11.

    Article  PubMed  Google Scholar 

  41. •• Fullerton HJ and Steinberg GR. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes 2010;59(3):551–3. This is a good review of the actions of AMPK and how they may be responsible for the beneficial effects of resveratrol.

    Article  PubMed  CAS  Google Scholar 

  42. Franco OH, Peeters A, Bonneux L, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46(2):280–6.

    Article  PubMed  CAS  Google Scholar 

  43. Rivera L, Moron R, Zarzuelo A, et al. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053–63.

    Article  PubMed  CAS  Google Scholar 

  44. Behbahani J, Thandapilly SJ, Louis XL, et al. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens. 2010;23(12):1273–8.

    Article  PubMed  CAS  Google Scholar 

  45. •• Mukhopadhyay P, Mukherjee S, Ahsan K, et al. Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One. 2010;5(12):e15705. This is one of the few studies examining the protective effects of resveratrol against ischemia-reperfusion injury, and it reports a unique mechanism for these effects.

    Article  PubMed  CAS  Google Scholar 

  46. Hung LM, Su MJ, Chen JK. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med. 2004;36(6):774–81.

    Article  PubMed  CAS  Google Scholar 

  47. Robich MP, Osipov RM, Chu LM, et al. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur J Pharmacol. 2011;664:45–53.

    Article  PubMed  CAS  Google Scholar 

  48. •• Patel KR, Scott E, Brown VA, et al. Clinical trials of resveratrol. Ann N Y Acad Sci. 2011(1214):161–9. This is a concise and comprehensive review of the registered clinical trials of resveratrol that have been completed to date.

    Article  Google Scholar 

  49. Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003–11.

    Article  PubMed  CAS  Google Scholar 

  50. Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010;91(6):1590–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

L.M. Chu: none; A.D. Lassaletta: none; M.P. Robich: none; F.W. Sellke: consultant for NovoNordisk and Cubist Pharmaceuticals, expert testimony for Pfizer in litigation regarding Celebrex.

Author information

Authors and Affiliations

  1. Division of Cardiothoracic Surgery, Department of Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USA

    Louis M. Chu, Antonio D. Lassaletta & Frank W. Sellke

  2. Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Michael P. Robich

  3. Division of Cardiothoracic Surgery, Alpert Medical School, Brown University, 593 Eddy Street, APC 424, Providence, RI, 02903, USA

    Frank W. Sellke

Authors
  1. Louis M. Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio D. Lassaletta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael P. Robich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frank W. Sellke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank W. Sellke.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s11883-011-0213-0

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chu, L.M., Lassaletta, A.D., Robich, M.P. et al. Resveratrol in the Prevention and Treatment of Coronary Artery Disease. Curr Atheroscler Rep 13, 439–446 (2011). https://doi.org/10.1007/s11883-011-0202-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-011-0202-3

Keywords

Search

Navigation